Brief Growth Ideas: ASML: No Clarification on 2026, China Procurement in Excess of End-Demand, High NA Start in 2028 and more
In this briefing: ASML: No Clarification on 2026, China Procurement in Excess of End-Demand, High NA Start in 2028 Ryman Healthcare Another Step In The Right Direction Fibocom A/H Listing: Wide A/H Premium but Expensive Valuation Top Toy International Pre-IPO Tearsheet The Beat Ideas: Sunshield Chemicals - Niche Chemistry Leadership Anchored by Promoter Expertise 1. ASML: No Clarification on 2026, China Procurement in Excess of End-Demand, High NA Start in 2028 Positive Management tone, as always, but no material clarification on 2026 revenues: China down (back to normal), Low NA EUV increase, some High NA but thats still pre-production. ASML has many qualities: monopoly, litho intensity increasing. Downside risks: how low China revenue go, is Mngt still double counting TSMC + Intel capacity, expectations for High NA too high? ASML is a lot more expensive than AMD, NVDA, MU, SK, TSM for very low growth. I don't like Broadcom for same reason: better Price / Growth in AMD, NVDA. 2. Ryman Healthcare Another Step In The Right Direction RYM has now upgraded FY26 sales expectations twice in just three months.